physician-scientist Leisha A. Emens, M.D., Ph.D., has been presented with the Sy Holzer Endowed Immunotherapy Research Fund Award to advance innovative research in cancer. Internationally recognized for her work in breast cancer immunotherapy, Emens is co-leader of the Cancer Immunology and Immunotherapy Program and director of Translational Immunotherapy for the Women’s Cancer Research Center at UPMC Hillman.
Emens has developed innovative combination immunotherapies that incorporate cancer vaccines, immune checkpoint inhibitors and other immune modulators with standard and novel treatments for breast cancer. She plays a vital role in leading the effort to advance translational cancer immunotherapy at UPMC Hillman and was the first to show that a combination of immunotherapy and chemotherapy can extend the lives of women with triple negative breast cancer. Her research led to accelerated approval by the U.S. Food and Drug Administration for this treatment to address one of the
Society for Immunotherapy of Cancer Announces Mary Dean, JD, CAE, as its Executive Director
PRWeb
FacebookTwitterEmail
MILWAUKEE (PRWEB) January 25, 2021
The Society for Immunotherapy of Cancer (SITC), the world’s leading membership-driven organization dedicated solely to cancer immunotherapy, is pleased to announce that Mary Dean, JD, CAE, has been named Executive Director of the association.
Ms. Dean steps into her new role after serving as the Associate Executive Director of SITC since February 2018, helping steward the strategic vision of the society as set forth by its members. She has more than 16 years of association experience. She spent the majority of those years serving as the Executive Director for the American Society of Gene & Cell Therapy, in addition to the Executive Director for the Society of Behavioral Medicine, American Venous Forum, and Growing Spine Foundation.
TACTI-002 study expanded in lung cancer
New phase II trial in head and neck cancer announced
EOC Pharma starts new phase II study in metastatic breast cancer
Robust operational and financial position, with $54.9 million in cash as at 31 December 2020, providing cash runway beyond the end of calendar year 2022
Sydney, AUSTRALIA, Jan. 22, 2021 (GLOBE NEWSWIRE) Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, provides an update on the ongoing development of its product candidates, eftilagimod alpha (“efti” or “IMP321”) and IMP761, and the activities of its partners.
Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research
Research Veteran Brings More than 30 Years of Industry and NIH Experience to Kite Leadership Team Kite, a Gilead Company today announced that Francesco Marincola, MD, will join the company as Senior Vice President and Global Head of Cell Therapy Research, effective February 1. Dr. Marincola will lead Kite’s Research organization across hematological malignancies and solid tumors. “Franco’s proven track … Research Veteran Brings More than 30 Years of Industry and NIH Experience to Kite Leadership Team Kite, a Gilead Company (Nasdaq: GILD), today announced that Francesco Marincola, MD, will join the company as Senior Vice President and Global Head of Cell Therapy Research, effective February 1. Dr. Marincola will lead Kite’s Research organization across hematological malignancies and solid tumors.
News Category Global Banking & Finance Reviews
Istari Oncology Announces FDA Grants Orphan Drug Designation for PVSRIPO for the Treatment of Advanced Melanoma
Istari Oncology Announces FDA Grants Orphan Drug Designation for PVSRIPO for the Treatment of Advanced Melanoma Istari Oncology, Inc., a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for PVSRIPO for the treatment of advanced melanoma (stage IIB-IV). PVSRIPO is a novel viral immunotherapy, based on the Sabin type 1 polio vaccine, that activates a patients innate and adaptive immune system to facilitate an anti-tumor response and establish long-term immunologic memory to help prevent the cancers return.